Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $145.84 | 8 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $40.58 | 2 | $0 (2023) |
| Lilly USA, LLC | $36.11 | 2 | $0 (2024) |
| Novo Nordisk Inc | $32.41 | 2 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.95 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $16.79 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $71.57 | 4 | Novo Nordisk Inc ($32.41) |
| 2023 | $74.27 | 4 | ABBVIE INC. ($40.58) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: Diabetes | ||||||
| 05/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: RESPIRATORY | ||||||
| 03/11/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Diabetes | ||||||
| 01/09/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Diabetes | ||||||
| 10/23/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: Respiratory | ||||||
| 10/15/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Diabetes | ||||||
| 10/12/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 22 | 36 | $5,512 | $2,331 |
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 36 | $5,512 | $2,331 | 42.3% |
About Dr. Jon Humphrey, M.D
Dr. Jon Humphrey, M.D is a Sports Medicine healthcare provider based in Carbondale, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1699972893.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jon Humphrey, M.D has received a total of $145.84 in payments from pharmaceutical and medical device companies, with $71.57 received in 2024. These payments were reported across 8 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($145.84).
As a Medicare-enrolled provider, Humphrey has provided services to 22 Medicare beneficiaries, totaling 36 services with total Medicare billing of $2,331. Data is available for 1 year (2023–2023), covering 1 distinct procedure/service records.
Practice Information
- Specialty Sports Medicine
- Other Specialties Family Medicine
- Location Carbondale, IL
- Active Since 06/29/2007
- Last Updated 06/10/2024
- Taxonomy Code 207QS0010X
- Entity Type Individual
- NPI Number 1699972893
Products in Payments
- MOUNJARO (Drug) $36.11
- Rybelsus (Drug) $32.41
- VRAYLAR (Drug) $22.24
- OFEV (Drug) $19.95
- UBRELVY (Drug) $18.34
- AIRSUPRA (Drug) $16.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.